TWST
HealthcareTwist Bioscience Corporation
$34.34
+$1.95 (+6.02%)
Jan 5, 2026
Price History (1Y)
Analysis
Twist Bioscience Corporation is a healthcare company operating in the diagnostics and research industry. With a market capitalization of $2.10 billion, it has a substantial scale compared to its peers. The company employs approximately 979 individuals. The financial health of Twist Bioscience appears to be challenging, with net income of -$77,670,000 over the trailing twelve months. This is reflected in negative profitability metrics, including an operating margin of -30.2% and a profit margin of -20.6%. The company's returns on equity (-16.4%) and assets (-13.6%) are also negative. In terms of its balance sheet, Twist Bioscience has $90.57 million in debt and $232.43 million in cash. The valuation context for Twist Bioscience is characterized by a forward P/E ratio of -16.75. The company's revenue growth rate over the past year was 16.9%. However, dividend information is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $2.10B
- P/E Ratio
- N/A
- 52-Week High
- $55.33
- 52-Week Low
- $23.30
- Avg Volume
- 1.58M
- Beta
- 2.19
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NMS
- Country
- United States
- Employees
- 979